(Papers to be published in Hastings Science and Technology Law Journal)
When patents on branded drugs expire and generics enter the market, drug prices tend to drop dramatically. As a result, getting generic drugs on the shelves is an important part of controlling health care costs. In recent years, however, drug companies have found increasingly creative methods of filing suits, striking deals, and entering into settlements that have the effect of delaying or lessening generic competition. Are these arrangements problematic under current law? What role can antitrust law play in monitoring them?
Business Meeting at Program Conclusion.